BIAF

bioAffinity Technologies, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website bioaffinitytech.com
Employees(FY) 14
ISIN US09076W1099

Performance

+1.95%

-25.35%

-50.61%

-47.75%

-32.49%

YTD

-37.56%

Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Advanced Technical Analysis

Technical Analysis of BIAF 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong downward pressure, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 25 reinforces the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to b...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BIAF

Stock Rank

Recent News & Updates

2024-12-16 19:00
Join bioAffinity Technologies Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19(Yahoo Finance)
2024-12-11 19:00
bioAffinity Technologies Set for Continued Expansion in 2025(Businesswire)
2024-12-04 19:00
Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule(Businesswire)
2024-11-13 19:00
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024(Businesswire)
2024-11-03 19:00
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development(Businesswire)
2024-10-29 20:00
bioAffinity Technologies Announces Award of Japanese Patent for CyPath Lung(Businesswire)
2024-10-20 23:39
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement(Prnewswire)
2024-10-20 22:45
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement(Businesswire)
2024-10-18 02:57
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement(Prnewswire)
2024-10-18 00:45
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement(Businesswire)
2024-10-15 20:00
bioAffinitys CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines(Businesswire)
2024-10-09 20:00
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer(Businesswire)
2024-10-08 20:00
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test(Businesswire)
2024-09-17 20:00
Peer-Reviewed Study: bioAffinity Technologies CyPath Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis(Businesswire)
2024-08-23 05:15
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO(Businesswire)
2024-08-13 21:25
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath Lung Sales(Businesswire)
2024-08-05 02:00
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million(Prnewswire)
2024-08-05 01:17
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million(Businesswire)
2024-08-01 22:00
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million(Prnewswire)
2024-08-01 21:25
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million(Businesswire)
2024-07-11 21:35
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-07-08 20:00
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath Lung(Businesswire)
2024-07-04 21:00
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-06-11 20:00
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath Lung Tests(Businesswire)
2024-05-15 09:55
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024(Investorplace)
2024-05-14 21:15
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath Lung Sales and Increased Laboratory Volumes(Businesswire)
2024-05-01 20:00
bioAffinity Technologies News Update(Businesswire)
2024-04-23 20:00
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth(Businesswire)
2024-04-08 20:00
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening(Businesswire)
2024-04-01 10:53
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023(Investorplace)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.